

Grants, Awards and Contracts

Albin, M., (J.J. Warsh, Supervisor) *Ontario Graduate Scholarship in Science and Technology Program.* Ontario Ministry of Training and Education

Ashley, M.J., Cohen, J., Ferrence, R., Burman, D. & Brewster, J. *Education of Canadian pharmacists in smoking cessation: Is it in step with developments in drug regulation?* Social Sciences and Humanities Research Council of Canada

Ashley, M.J., Ferrence, R., Burman, D., Cohen, J., Dunsdon, J. & Poston, J. *On the front line: Expanding roles of pharmacists in smoking cessation.* National Cancer Institute of Canada

Bagby, R.M. *The assessment of malingering and defensive responding on the Minnesota Multiphasic Personality Inventory - 2.* Social Sciences and Humanities Research Council of Canada

Bagby, R.M. *Development of a natural practice laboratory for the study of major depression.* Eli Lilly Canada Inc.

Bagby, R.M. *Evaluation and revision of Hamilton Rating Scale for Depression.* Eli Lilly Canada Inc.

Bagby, R.M. *Personality and major depression: Predicting treatment outcome and neuropsychological status.* National Institutes of Health

Bagby, R.M. *Personality as a predictor of relapse and recurrence of major depression.* National Institutes of Health

Barbaree, H. *Approaches to assessing risk for reoffense in sex offenders: A comparison of the predictive validity of actuarial and structured clinical assessment instruments.* CAMH Research Fund Award

Barr, C. & Kennedy, J.L. *Investigation of genetic factors in attention deficit hyperactivity disorder.* Canadian Institutes of Health Research

Barr, C., Kovacs, M. & Kennedy, J.L. *Risk factors in childhood-onset depression (supplement).* National Institutes of Mental Health

Barr, C., Lovett, M., Beitchman, J., Humphries, T., Tannock, R. & Macciardi, F. *Genetics of reading disabilities.* Canadian Institutes of Health Research

Basile, V. *Uncovering genetic risk factors for clozapine induced weight gain side-effects in schizophrenia.* CAMH Research Fund Award

Bassett, A. *Looking back, looking ahead.* Connaught Foundation

Bassett, A., Brzustowicz, L., Honer, W., Husted, J. & Chow, E. *Localizing genes for familial schizophrenia.* Canadian Institutes of Health Research

Bassett, A., Chow, E. & Husted, J. *Refining the behavioural phenotype of schizophrenia.* Ontario Mental Health Foundation

Bassett, A., Chow, E. & Weksberg, R. *Physical and psychiatric phenotype of adults with congenital heart defects and a genetic syndrome.* Ontario Mental Health Foundation

Bassett, A., Chow, E., Weksberg, R., Brzustowicz, L., Siu, S., Zipursky, R. & Husted, J. *A Screening strategy for a genetic subtype of schizophrenia.* Canadian Institutes of Health Research

Bassett, A., Chow, E., Weksberg, R. & Zipursky, R.B. *Deletion 22q11 and velocardiofacial syndrome: The delineation of a distinct genetic subtype of schizophrenia?* Scottish Rite Schizophrenia Research Program

Bassett, A. & Dickson, R. *Determining a screening method to identify a genetic subtype of schizophrenia.* Ian Douglas Bebensee Foundation

Bassett, A., Husted, J. & Chow, E. *Refining the behavioural phenotype of familial schizophrenia.* Bill Jeffries Schizophrenia Endowment Fund

Beal, G. *Constituting community following a long-term psychiatric hospitalization.* CAMH Research Fund Award

Beiser, M. *Education Media Project Immigration and Refugee Issues Computer Assisted Learning (EMPIRICAL).* Citizenship and Immigration Canada

Beiser, M. *Online Content Enhancement Project.* Citizenship and Immigration Canada

Beiser, M. *Strangers Becoming Us, an educational curriculum for Canadian elementary schools, grades four to eight.* Citizenship and Immigration Canada

Beiser, M. *Strangers Becoming Us, an educational curriculum for Canadian high schools.* Citizenship and Immigration Canada

Beiser, M. *Strangers Becoming Us: Creating a template for public school curricula on immigration.* The Maytree Foundation

Beiser, M., Amrhein, C., Lanphier, M. & Killbride, K. *Centre of Excellence for Research on Immigration and Settlement (CERIS).* Social Sciences and Humanities Research Council of Canada

- Beiser, M. & Keystone, J.** *Stress and tuberculosis among immigrants and refugees in Canada.* Canadian Institutes of Health Research
- Beiser, M. & Noh, S.** *A community in distress: Mental health in the Tamil community.* Canadian Institutes of Health Research
- Beiser, M., Noh, S., Rummens, A., Kaspar, V., Khanlou, N. & Fenta, H.** *The New Canadian Children Youth Study (NCCYS): Toronto.* Canadian Heritage
- Beiser, M. & Rummens, A.** *Immigrant perceptions of mental illness and their use of mental health services.* Social Sciences and Humanities Research Council of Canada
- Beiser, M., Simich, L. & Mauricette, R.** *Alone in Canada: A self-help manual for single newcomers.* OASIS (CIC)
- Beiser, M., Simich, L., Noh, S., Rummens, A. & Kaspar, V.** *The New Canadian Children and Youth Study (NCCYS): Toronto — Pilot Study.* Citizenship and Immigration Canada
- Beitchman, J. & Broder, E.** *Telepsychiatry for remote and rural Ontario.* Ministry of Community and Social Services
- Bercovitz, K., Stewart, D. & Ferrence R.** *Smoking cessation, reduction, and relapse among postpartum women.* Canadian Tobacco Research Initiative, National Cancer Institute of Canada
- Bettazzoni, M.** *Research Grant Award.* Canadian Occupational Therapy Foundation
- Blanchard, R., Christensen, B.K. & Dickey, R.** *Cognitive functioning in pedophiles.* Social Sciences and Humanities Research Council of Canada
- Boughton, R.** *Barriers to treatment and treatment service needs of the female problem gambler.* Ontario Problem Gambling Research Council
- Boydell, K. & Trainor, J.** *CMHEI Project: A longitudinal evaluation of family initiatives in Ontario.* Ontario Mental Health Foundation
- Bradwejn, J., Segal, Z.V., Kosczyk, D. & Boulenger, J.P.** *Self administered CBT versus Sertraline for the treatment of panic disorder.* Canadian Institutes of Health Research/PMAC
- Brands, B.** *Adolescent heroin use – bridging the gap to treatment.* CAMH Research Fund Award
- Brands, B., Marsh, D., Busto, U. & Bigelow, G.** *Comparative study of the subjective and physiological effects of heroin and hydromorphone administered intravenously versus subcutaneously.* Open Society Institute
- Brown, G., Katzman, M., Sinson, R. & Antony, M.** *Brain function in panic disorder: PET studies.* Canadian Institutes of Health Research
- Bryden, P. (B. Toner, Supervisor).** *Development of a body image group manual for adolescents with eating problems.* Eli Lilly Canada Inc.
- Busto, U.** *Prescription opioid dependence – new strategies.* CAMH Research Fund Award
- Busto, U., Naranjo, C. & Herrmann, N.** *The role of the brain reward system in depression.* Ontario Mental Health Foundation
- Cameron, R., Ferrence, R., McDonald, P., Ashley, M.J., Brown, K.S., Campbell, S., Cohen, J., Elliott, S., Eyles, J., Fong, G., Garcia, J., Lavack, A., Lovato, C., Smith, P. & Sparks, R.** *A national network for research on tobacco control: Letter of intent.* Canadian Institutes of Health Research: Interdisciplinary Health Research Teams Program
- Campbell, S.H., Ashley, M.J., Bero, L., Bridgen, L., Casebeer, A. Gibbons, R., Sletton, M., Cohen, J., Ferrence, R. & Moyer, C.** *Framing the tobacco issue: Does the frame affect the outcome?* Canadian Tobacco Research Initiative, National Cancer Institute of Canada
- Campbell, S.H., Wakefield, M., Chaloupka, F., Borland, R., Scollo, M., Hastings, G., MacFayden, L., Ferrence, R. & Cohen, J.** *International tobacco marketing surveillance.* Canadian Tobacco Research Initiative, National Cancer Institute of Canada.
- Chang, A. (J.J. Warsh, Supervisor).** *Doctoral Research Award.* Canadian Institutes of Health Research
- Christensen, B.** *Inhibitory deficits and depressive relapse.* CAMH Research Fund Award
- Christensen, B. & Bagby, M.** *Neuropsychological instrumentation project.* Eli Lilly Canada Inc.
- Cleland, P., Jarrett, M. & Bhaleran, S.** *Developing, disseminating and evaluating an educational package to cross-train TBI and substance abuse clinicians.* Ontario Neurotrauma Foundation
- Cohen, J., Abernathy, T., Adlaf, E., Ashley, M.J. & Ferrence, R.** *Support for tobacco control policy measures: multi-level analysis.* Social Sciences and Humanities Research Council, Canadian Tobacco Research Initiative Planning Grant
- Cohen, J., Ashley, M.J., Ferrence, R., Rehm, J. & Northrup, D.** *Factors associated with legislators' support for tobacco control and other public health measures.* National Health Research and Development Program

- Cohen, J., Ashley, M.J., Ferrence, R. & Steward, D.** *Institutional addiction to tobacco: defining links between the tobacco industry and academic and health institutes.* National Cancer Institute of Canada
- Collins, J., Skinner, W. & Toneatto, T.** *Beyond assessment: The impact of comorbidity of pathological gambling, psychiatric disorders and substance use disorders on treatment course and outcome.* Ontario Problem Gambling Research Council
- Cooke, R.G.** *Primary care psychiatry course, Sault Ste. Marie. CME programme for rural and isolated physicians.* Ontario Ministry of Health and Long-Term Care
- Cooke, R.G. & Kennedy, S.H.** *The Economic evaluation of Reboxetine using conjoint analysis in patients with major depressive disorder.* Innovus Research Inc.
- Cooke, R.G. & Kennedy, S.H.** *Utility and quality of life assessment in depression, pilot phase* Innovus Inc.. Innovus, Research Inc.
- Cooke, R., Kennedy, S.H., McIntyre, R., Katzman, M., Schwartz, M. & Srinivasan, J.** *A multicenter, pivotal, safety and efficacy study of the NeuroCybernetic Prosthesis System in patients with depression.* Cyberonics Inc.
- Corrigall, W.A.** *Cholinergic and opiate mechanisms in drug reinforcement.* National Institute on Drug Abuse
- Corrigall, W.A.** *Nicotine addiction: Potential therapeutics.* Addiction Therapies, Inc.
- Corrigall, W.A., Zack, M. & Eissenberg, T.** *Adolescent smoking: A biobehavioural approach to understanding the patterns of and the trajectory to nicotine dependence.* Robert Wood Johnson Foundation
- Corson, T. (J.J. Warsh, Supervisor).** *Doctoral fellowship.* Natural Sciences and Engineering Research Council
- Corson, T. (J.J. Warsh, Supervisor).** *Merit scholarship.* Institute of Medical Science. University of Toronto
- Cunningham, J.** *Providing personalized assessment feedback for problem drinking on the internet.* CAMH Research Fund Award
- Cunningham, J.** *The impact of self-help materials for problem drinkers: Population studies.* Canadian Institutes of Health Research
- Cunningham, J., Koski-Jannes, A. & Wild, T.C.** *Treating alcohol problems with self-help materials.* National Institute on Alcohol Abuse and Alcoholism
- DaSilva, J.** *Development of new dopamine D1 agonist radioligands for studying D1 receptors with PET.* Canadian Institutes of Health Research
- DaSilva, J.** *R-[C-11]Rolipram as a prototypical probe for the cAMP-specific PDE4 second messenger system - Part I.* Eli Lilly Canada Inc.
- DaSilva, J.** *R-[C-11]Rolipram as a prototypical probe for the cAMP-specific PDE4 second messenger system - Part II.* Eli Lilly Canada Inc.
- DaSilva, J.** *R-[C-11]Rolipram as a prototypical probe for the cAMP-specific PDE4 second messenger system - Part III.* Eli Lilly Canada Inc.
- DaSilva, J., Guttman, M. & Houle, S.** *PET imaging of hemiparkinsonian patients with D1 agonist R-[C-11]SKF 82957.* Parkinson Foundation of Canada
- Daskalakis, Z.J.** *A study of intracortical inhibition and facilitation in schizophrenia using transcranial magnetic stimulation (research training fellowship).* Ontario Mental Health Foundation
- Degutis, L., Giesbrecht, N., Cronebusch, C., Hingson, R., Mann, R., Macdonald, S., Stoduto, G. & Toomey, T.** *A comparative analysis of the passage and failure of DWI legislation and regulation in the U.S. and Canada.* Robert Wood Johnson Foundation
- Devins, G.M.** *Quality of life and psychosocial impact of chronic disease (senior scientist award).* Canadian Institutes of Health Research
- Devins, G.M., Beiser, B., Noh, S. & Llewellyn-Thomas, H.** *Gender and ethnocultural moderators of illness intrusiveness across the life span.* Canadian Institutes of Health Research
- Dewa, C., Goering, P. & Lin, E.** *Depression in the workplace: Assessing treatment and predicting disability.* Ontario Round Table on Appropriate Prescribing
- Dresser, J. & Gliksman, L.** *Comparing two legislative approaches to serve education.* National Institute on Alcohol Abuse and Alcoholism
- Dunn, E.** *Analysis of fentanyl in rabbit plasma samples.* Delex Therapeutics
- Durbin, J. & Ochocka, J.** *Dual diagnosis resource service evaluation plan development phase I and II.* Dual Diagnosis Resource Service
- Durbin, J., Rogers, J., Macfarlane, D., Cochrane, J. & Goering, P.** *Best practices in mental health systems integration.* Ontario Mental Health Foundation
- Endler, N.E. & Rector, N.A.** *State-trait anxiety and coping in the anxiety spectrum.* York University
- Erickson, P. & Adlaf, E.** *A cross national study of the youth drugs-violence nexus.* National Institute on Drug Abuse
- Esplen, M.J., Hunter, J., Leszcz, M., Glendon, G., Toner, B. & Stuckless, N.** *Genetic predisposition to cancer: The impact on individuals, families and*

society. Change Foundation 1998 Grants Program, Ontario Hospital Association

Esplen, M.J., Madlensky, L., Leszcz, M., Toner, B. & Wong, J. *Development of a group intervention for HNPCC gene carriers.* National Cancer Institute of Canada

Gemar, M. *Markers of vulnerability in first-degree relatives of depression probands.* CAMH Research Fund Award

Ferrence, R., Ashley, M.J., Brown, K.S., Cohen, J., McDonald, P. & Stephens, T. *A plan for enhanced surveillance, evaluation, and research under the renewed Ontario Tobacco Strategy.* Ontario Ministry of Health and Long-Term Care

Ferrence R., Ashley, M.J., Brown, K.S., Cohen, J., McDonald, P. & Stephens, T. *Youth and evaluation and monitoring.* Ontario Ministry of Health and Long-Term Care

Ferrence, R., Ashley, M.J., Bull, S., Cohen, J., Lovato, C. & Potvin, L. *A national study on environmental tobacco smoke in the home.* National Cancer Institute of Canada/Cancer Care Society

Ferrence, R., Ashley, M.J., Cohen, J., Selby, P. & Boadway, T. *Protecting children's health: The role of primary care physicians in reducing exposure to environmental tobacco smoke.* Canadian Tobacco Research Initiative, National Cancer Institute of Canada

Fischer, B. *Illicit opiate addiction: A cross-disciplinary, comprehensive and concerted research initiative (IHRT proposal development).* Canadian Institutes of Health Research

Fischer, B. *Over time analysis of injection drug use related harms and determinants in western jurisdictions.* Connaught Foundation

Fischer, B. *Social, legal and feasibility research for a North American heroin prescription trial.* Open Society Institute

Fischer, B. & Wortley, S. *Evaluation study of Toronto Prostitution Offender Diversion Project.* National Crime Prevention Centre

Fitzmaurice, P. (S.J. Kish, Supervisor). *Research fellowship.* The Society for Progressive Supranuclear Palsy

Fletcher, P.J. *Career Scientist Award.* Ontario Ministry of Health and Long-Term Care

Fletcher, P.J. *The role of the ventral pallidum in mediating drug reinforcement.* NSERC

Fletcher, P.J. *Serotonin-dopamine interactions and reward related behaviour.* Canadian Institutes of Health Research

Fletcher, P.J. & Sill, T.L. *Prefrontal cortex monoamines and behaviour.* Canadian Institutes of Health Research

Fornazzari, L. *Early detection of mild cognitive impairment.* Ontario Ministry of Health and Long-Term Care

George, S.R. & O'Dowd, B.F. *Dopamine and opioid systems in brain: Substrates for nicotine abuse.* Smokeless Tobacco Research Council

George, S.R. & O'Dowd, B.F. *Identification and characterization of novel GPCR genes.* Merck Frosst Canada Inc.

George, S.R. & O'Dowd, B.F. *Neuropeptide receptors and ligands.* Canadian Institutes of Health Research

Giesbrecht, N., Norstrom, T., Mackenzie, B., Ramstedt, M., Room, R. & Osterberg, E. *Canadian Nordic Alcohol Policy Project: Availability and alcohol problems — The relevance of the Canadian experiences for the Nordic countries.* Centre for Social Research on Alcohol and Drugs

Ginovart N., Kapur, S. & Houle, S. *Can dopamine D2 receptor upregulation by antipsychotics be avoided by a different regimen of occupancy kinetics? A longitudinal [¹¹C]-raclopride PET study.* National Alliance for Research on Schizophrenia and Depression

Ginovart, N., Wilson, A.A. & Houle, S. *In vivo characterization of potential radioligands for imaging the serotonin transporter: Leads for the development of in vivo strategies to evaluate serotonergic dysfunctions using positron emission tomography.* Connaught Foundation

Gliksman, L., Allison, K. & Parikh, K. *An evaluation of the WHO mental disorders in primary care (Ontario).* Ontario Ministry of Health and Long-Term Care

Gliksman, L., Allison, K., Parikh, K. & Baudoin, F. *An evaluation of the WHO mental disorders in primary care (New Brunswick).* New Brunswick Ministry of Health

Gliksman, L., Baudoin, F., Allison, K. & Parikh, K. *Mental disorders in primary care.* Ontario Ministry of Health and Long-Term Care

Gliksman, L., LaPrairie, C., Erickson, P. & Wall, R. *An evaluation of the Toronto Drug Treatment Court program.* National Crime and Prevention Centre/Department of Justice

Goering, P. *Canadian Health Services Research Foundation Chair Award.* CHSRF/Canadian Institutes of Health Research

Goering, P. *Community Mental Health Evaluation Initiative Coordinating Centre.* Ontario Mental Health Foundation

- Goering, P., Bradley, S., Leavey, J. & Macfarlane, D.** *Appropriate "best-practice" continuum of mental health services for transitional youth.* Essex, Kent and Lambton District Health Council
- Goering, P., Butterill, D. & Wasylenki, D.** *External review and analysis of the current utilization of acute adult psychiatric beds.* Alberta Mental Health Board
- Goering, P., Macfarlane, D., Durbin, J., Sheldon, T. & Palmer, H.** *Community Comprehensive Assessment Project.* Northeastern, Champlain Implementation Task Force, Grand River DHC
- Goering, P., Macfarlane, D., Palmer, H., Butterill, D., Cochrane, J., Durbin, J. & Sheldon, T.** *Northeastern Comprehensive Assessment Project.* North Region/Health Care Programs Division, Ontario Ministry of Health and Long-Term Care
- Goering, P., Macfarlane, D., Palmer, H., Stuart, H., Butterill, D., Cochrane, J. & Durbin, J.** *Kingston Psychiatric Hospital Comprehensive Assessment Project.* Ontario Ministry of Health and Long-Term Care
- Goering, P., Macfarlane, D. & Rogers, J.** *Consultation report for Muskoka-Parry Sound Community Mental Health Services.* Muskoka-Parry Sound Community Mental Health Service
- Goering, P. & Rogers, J.** *London Mental Health Crisis Service.* London Mental Health Crisis Service
- Goering, P., Rogers, J., Butterill, D. & Wasylenki, D.** *Niagara Health System Project.* Niagara Health System
- Goering, P., Rogers, J., Dewa, C. & Kates, N.** *Best Practice approaches to meeting the needs of individuals who are not SMI.* Essex, Kent and Lambton District Health Council
- Goering, P., Wasylenki, D. & Gehrs, M.** *External review of the mental health crisis response services in Sarnia/Lambton.* Essex, Kent and Lambton District Health Council
- Gotowiec, A.** *Postdoctoral fellowship.* Social Sciences and Humanities Research Council of Canada
- Gotowiec, A., Beiser, M., Goering, P. & Kilbride, K.** *Ethnic identity in adolescents and young adults of multi-ethnic heritage.* Multiculturalism Department of Canadian Heritage
- Graham, K., Osgood, W., Gliksman, L. & Bois., C.** *Safer Bars: Evaluating an intervention to reduce barroom aggression.* National Institute on Alcohol Abuse and Alcoholism
- Guttman, M.** *A phase III, double blind, placebo controlled study of the effect of Riluzole 50 mg Bid or 100 mg bid for two years on the progression of Parkinson's Disease in 1050 patients.* Aventis Pharma
- Guttman, M.** *A phase III, multicentre, double blind, parallel group placebo controlled study of the effect of Riluzole 50 mg bid or 100 mg bid for two years on the progression of Parkinson's Disease in patients treated with L-dopa and/or dopamine agonists.* Aventis Pharma
- Guttman, M.** *CARE-HD open label extension.* AstraZeneca
- Guttman, M.** *Center of Excellence Award.* National Parkinson Foundation
- Guttman, M.** *Clinical Assistance Program.* Parkinson Foundation of Canada
- Guttman, M.** *Huntington study group (HSG). PHAROS study.* University of Rochester/HSG
- Guttman, M. & Kieburz, K.** *Co-enzyme Q-10 and Remacemide: Evaluation in Huntington's disease.* National Institutes of Health
- Guttman, M. & Meyers, R.** *PD gene study.* National Institutes of Health
- Guttman, M. & Naylor, D.** *Pilot health economic project in Parkinson's Disease.* Parkinson Foundation of Canada
- Hachinski, V. & Dewa, C.** *The Canadian Stroke Network project.* Network of Centres of Excellence
- Hodgins, D., Toneatto, T., Makarchuk, K. & Skinner, W.** *Minimal treatment approaches for concerned significant others of problem gamblers.* Ontario Problem Gambling Research Council
- Houle, S. & Vaccarino, F.** *Functional Imaging Research Network: PET component.* Canadian Foundation for Innovation and Ontario Innovation Trust
- Husain, N., Afsar, S., Creed, F. & Chaudhry, I.** *Psychological morbidity medical clinics.* Pakistan Institute of Learning and Living
- Husted, J. & Bassett, A.** *Gene-environment interaction in familial schizophrenia.* National Alliance for Research on Schizophrenia and Depression
- Jain, U., Gojer, J., Barton, R. & Ben-Kuaz, R.** *Phase III randomized, double-blind, comparison of placebo Tomoxetine HCl in adult patients with DSM-IV ADHD.* Eli Lilly Canada Inc.
- Jain, U., Gojer, J. & Barton, R.** *Tomoxetine in the treatment of adults with ADHD.* Eli Lilly Canada Inc.
- Jain, U., Littman-Sharp, N. & Barton, R.** *Paroxetine in the treatment of pathological gambling.* SmithKline Beecham Pharma Ltd.
- Jain, U., Monga, S., Charach, A. & Barton, R.** *A randomized, multicenter, 8 week, double-blind, placebo-controlled, flexed dose study to evaluate the efficacy and safety of Paroxetine in children and adolescents with depression.* SmithKline Beecham Pharma Ltd.

- Jain, U., Young, A., Monga, S., Barton, R. & Manassis, K.** *A randomized, multicenter, 10 week, double-blind, placebo-controlled, flexible-dose study to evaluate the efficacy and safety of Paroxetine in children and adolescents with obsessive compulsive disorder.* SmithKline Beecham Pharma Ltd.
- Kapur, S.** *5HT1A receptors in schizophrenia: A PET investigation.* EJLB Foundation Scholar Program
- Kapur, S.** *Differential effects of continuous vs. transient dopamine receptor blockade: Implications for understanding antipsychotic action.* AstraZeneca
- Kapur, S.** *PET Investigations of endogenous dopamine and clinical response in schizophrenia (Clinical Scientist Award).* Canadian Institutes of Health Research
- Kapur, S., Apiquian-Guitart, R., Ulloa, E. & Nicolini, H.** *Amoxapine as treatment for schizophrenia - a proof of principle study.* Stanley Research Foundation
- Kapur, S. & Seeman, P.** *Brain receptor kinetics measurement and functional consequences as relevant to drug development.* Eli Lilly Canada Inc.
- Kapur, S., Seeman, P. & Baker, G.** *Dynamic aspects of drug-receptor interaction: Implications for antipsychotic action.* Stanley Research Foundation
- Kapur, S., Seeman, P. & McClelland, R.** *The development of a novel, potentially antipsychotic, compound.* Neuromolecular Inc.
- Kapur, S. & Zipursky, R.B.** *PET investigations of endogenous dopamine and clinical response in schizophrenia.* Canadian Institutes of Health Research
- Kapur, S., Zipursky, R.B. & Remington, G.** *Investigating the prolonged receptor effects of Olanzapine: A PET study.* Eli Lilly Canada Inc.
- Kaspar, V.** *Health and development of minority and immigrant youth.* Canadian Institutes of Health Research
- Kaspar, V. & Noh, S.** *Mental health of resettled and non-resettled youth with lifetime exposure to war-related traumatic events.* Social Sciences and Humanities Research Council of Canada
- Kaspar, V., Noh, S. & Rummens, J.** *Stress, coping, and psycho-social adaptation among children and adolescents of war.* Social Sciences and Humanities Research Council of Canada
- Katz, M. & Devins, G.** *A randomized controlled trial of psychoeducation vs. standard care in oral cancer patients.* National Cancer Institute of Canada
- Katzman, D.K., Zipursky, R.B., Christensen, B., Young, A. & Mikulis, D.** *Brain structure and functioning adolescent-onset anorexia nervosa.* Ontario Mental Health Foundation
- Katzman, M.** *Effects of tryptophan depletion on the central and peripheral chemoreflexes in panic disorder patients and health volunteers.* CAMH Research Fund Award
- Katzman, M., Richter, M. & Cheok, A.** *A double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of flexible dosages of 10-20 mg Lu 26-056 in social phobia.* Lundbeck Canada Inc.
- Kennedy, J.L.** *Genetic studies of psychosis in Portugal.* National Institutes of Mental Health
- Kennedy, J.L. & Barr, C.** *Supplement to risk factors in childhood-onset depression.* National Institutes of Health
- Kennedy, J.L., Petronis, A. & Macciardi, F.M.** *Strategies for gene discovery in schizophrenia.* Canadian Institutes of Health Research
- Kennedy, S.H., Cooke, R., McIntyre, R.S. & Srinivasan, J.** *A multi centre, double-blind randomized sertraline-controlled efficacy and safety trial with mirtazapine (Remeron) in subjects with a major depressive episode.* NV Organon
- Kennedy, S.H., Cooke, R., McIntyre, R.S. & Srinivasan, J.** *An open-label one year trial of flibanserin in depressed patients, in North America and Australia (511.44).* Boehringer Ingelheim Canada Ltd.
- Kennedy, S.H. & Grigoriadis, S.** *Reproductive biology and depression in post menopausal women — role of a selective estrogen receptor modulator.* Younger Foundation
- Kennedy, S.H., Houle, S. & Kapur, S.** *A Comparative positron emission tomography study of 5HT2 receptors in patients with major depression and in healthy volunteers.* Canadian Institutes of Health Research
- Kennedy, S.H., McIntyre, R.S. & Cooke, R.S.** *An 8-week randomized double-blind, placebo controlled, parallel group efficacy and safety trial of flibanserin and paroxetine in titrated dosages in outpatients with major depressive disorder. (511.42).* Boehringer Ingelheim Canada Ltd.
- Kennedy, S.H., McIntyre, R.S., Cooke, R.S. & Srinivasan, J.** *An 8-week, multicentre, double-blind, double-dummy, randomized, parallel group study comparing the effects of 20 mg of paroxetine to 150 mg of Welbutrin SR in patients with major depressive disorder.* Glaxo Wellcome Inc.
- Kennedy, S.H., McIntyre, R.S., Cooke, R.S. & Srinivasan, J.** *The efficacy, safety and tolerability of robalzotan in patients with major depressive disorder. A paroxetine and placebo controlled 8-week study.* AstraZeneca

- Khanlou, N.** *Mental health outcomes of immigrant and refugee secondary school students (postdoctoral fellowship).* Canadian Institutes of Health Research
- Khanlou, N., Beiser, M., Cole, E., Freire, M., Hyman, I., & Kilbride, K.** *Towards context-specific mental health promotion policies and strategies among immigrant and refugee female adolescents.* Status of Women Canada
- Khoury, E. (J. Court, CAMH Archives Preceptor: Supervisor).** *Hannah Archives Internship.* Associated Medical Services Inc. / Hannah Institute for the History of Medicine
- King, G., DeWit, D., LaPorta, J., MacDougall, J., Meyer, K., Miller, L. & Offord, D.** *Predictors of Canadian children's mental health and competence: A structural equation modelling approach using the National Longitudinal Survey of Children and Youth.* Canadian Institutes of Health Research
- Kish, S., Warsh, J.J. & Nobrega, J.** *Brain neurochemistry of human methamphetamine users.* National Institutes on Drug Abuse
- Knapp, M.** *Development of recombinant adenovirus for in vivo gene transfer of dopamine receptors.* Ontario Mental Health Foundation
- Kovacs, M., Kennedy, J.L. & Barr, C.** *Risk factors in childhood onset-depression.* National Institutes of Health
- Kroll, R., Houle, S. & De Nil, L.** *An 150 H2O PET study of brain activity in stuttering: Differences from normal speech and changes following treatment.* Canadian Institutes of Health Research
- Lalumiere, M.** *Phallometric assessment of masochistic sexual preferences.* CAMH Research Fund Award
- Lam, R., Levitt, A., Levitan, R.D. & Szalai, J.P.** *A multicentre randomized controlled trial of light therapy vs. anti-depressants for seasonal affective disorder.* Canadian Institutes of Health Research
- Lancot, K., Kapur, S., Herrmann, N. & Black, S.E.** *PET study of 5HT1A receptors in Alzheimer's disease.* Alzheimer's Association, USA
- Langton, C. & Barbaree, H.** *Towards a model of risk management: The contributions of institutional treatment behaviour, dynamic risk factors, and supervision practices in the prediction of sex offender recidivism.* Association for the Treatment of Sexual Abusers
- Lau, M.** *Inhibitory deficits and depressive relapse.* CAMH Research Fund Award
- Lau, M.A., Christensen, B.K., Gemar, M. & Segal, Z.V.** *Inhibitory deficits in persons with major depressive disorder: Risk factor or correlate?* Canadian Institutes of Health Research
- Le, A.D.** *Effects of Lofexidine.* Forum Products
- Le, D.** *Stress and relapse to alcohol.* Ontario Mental Health Foundation
- Levitan, R.D., Masellis, M., Kennedy, S.H., Kaplan, A.S., Lam, R., Basile, V.S. & Macciardi, F.** *Polymorphism in serotonin system genes: Putative role in increased eating behaviour in seasonal affective disorder and bulimia nervosa.* Ontario Mental Health Foundation
- Levitan, R.D., Masellis, M., Kennedy, S.H., Kaplan, A.S., Lam, R., Basile, V.S. & Macciardi, F.** *Serotonin genetic variation and increased eating behaviour in seasonal affective disorder and bulimia nervosa.* Ontario Mental Health Foundation
- Levitan, R.D., Warsh, J.J. & Kennedy, J.L.** *Serotonin-induced Ca²⁺ mobilization in platelets: a biochemical phenotype to study bulimia nervosa and seasonal affective disorder.* National Alliance for Research on Schizophrenia and Depression
- Li, P.** *Alteration of gene expression in bipolar affective disorder.* National Alliance for Research on Schizophrenia and Depression
- Lin, E., Goering, P., Durbin, J. & Prendergast, P.** *Hospital Report 2001: mental health feasibility study.* University of Toronto and Ontario Hospital Association
- Links, P. & Strike, C.** *Access to health and mental health services: The perspective of violent men.* Health Canada
- Liu, F.** *Ligand gated and dopamine D1-like receptors protein interactions in schizophrenia.* Ontario Mental Health Foundation
- Liu, F.** *Ligand-gated GABA-A and dopamine D5 Receptor protein-protein interaction in post-mortem schizophrenia brain.* Canadian Psychiatric Research Foundation
- Liu, S.C.I. (J. Nobrega, Supervisor).** *Altered gene expression in schizophrenia.* Canadian Institutes of Health Research/Schizophrenia Society of Canada
- Macciardi, F.M.** *Haplotype Transmission Disequilibrium Test (H-TDT) of candidate genes for the susceptibility to schizophrenia on chromosome 22q11.* National Alliance for Research on Schizophrenia and Depression
- MacDonald, J.F., Atwood, H.L., Boulianne, G.L., Charlton, M.P., Roder, J., Trimble, W.S., Van Tol, H.H.M., Wang, Y.T. & Wang, L-Y.** *The synapse.* Canadian Institutes of Health Research
- MacDonald, J.F. & Van Tol, H.H.M.** *Calcium-sensing in hippocampal neurons.* Canadian Institutes of Health Research
- Macdonald, S., Mann, R., Chipman, M. & Adlaf, E.** *Impact of drug and alcohol abuse on traffic collisions*

and the effects of treatment. Canadian Institutes of Health Research

MacKay, S. & Henderson, J.M. *The arson prevention program for children (TAPP-C Ontario)*. City of Toronto Fire Service

MacKay, S. & Henderson, J.M. *The arson prevention program for children (TAPP-C Ontario)*. Ministry of the Solicitor General and Corrections and Fire Marshal's Public Fire Safety Council

Malla, A., Addington, D., Addington, J., Kopala, L., Norman, R. & Zipursky, R.B. *A Canadian consortium for prevention and early intervention of psychosis - CIHR Opportunity Fund*. Canadian Institutes of Health Research

Manassis, K., Arnold, P. & Richter, P. *Clinical and serological characteristics of insidious versus acute onset of obsessive compulsive disorder in childhood*. Hospital for Sick Children Endowment Fund

Mann, R., Smart, R., Vingilis, E., Beirness, D. & Stoduto, G. *Administrative license suspensions in Ontario: Evaluation of impact and tests of the differential deterrence hypothesis*. Alcoholic Beverage Medical Research Foundation

McCay, E. & Devins, G. *The Canadian group intervention research network: enhancing quality of life in chronic illness*. Social Sciences and Humanities Research Council of Canada

McCurley, R. & Diaz, P. *A multicenter, randomized, double-blind study of flexible doses of Aripiprazole vs. Perphenazine in the treatment of patients with treatment resistant schizophrenia*. Bristol-Myers Squibb

McIntyre, R., Kennedy, S., Parikh, P., Srinivasan, J. & Cooke, R. *An open trial to document the safety and efficacy of risperidone as add-on therapy to mood stabilizers in the treatment of the manic phase of bipolar disorder*. Janssen-Ortho Inc.

McIntyre, R., Kennedy, S.H. & Srinivasan, J. *Estimating the metabolic and reproductive endocrine effects of divalproex in females with bipolar disorder*. Glaxo Wellcome Inc.

McIntyre, R., Kennedy, S.H., Srinivasan, J., Parikh, S. & Cooke, R. *A metabolic comparative study of olanzapine and risperidone on body weight, leptin levels and lipid homeostasis in bipolar disorder*. Janssen-Ortho Inc.

McIntyre, R., Kennedy, S.H., Srinivasan, J. & Sagman, D. *Randomized, single-blind comparison of topiramate and bupropion SR as add-on therapy in bipolar depression*. Janssen-Ortho Inc.

McKarney, L. (H.H.M. Van Tol, Supervisor). *A transgenic mouse model for dopamine hyperactivity and psychosis*. Eli Lilly Zyprexa Research Fund

McMain, S. *Follow-up dialectical behaviour therapy for patients with concurrent substance use and borderline personality disorder*. CAMH Research Fund Award

Meyer, J.H. *Frontal cortex 5-HT₂ receptor binding potential in depression before and after treatment (Michael Smith Fellowship)*. Canadian Institutes of Health Research

Meyer, J.H., Houle, S., Kennedy, S. & Mayberg, H.S. *5-HT_{2A} receptors and treatment responsiveness during depression*. National Alliance for Research on Schizophrenia and Depression

Meyer, J.H., Kennedy, S.H. & Houle, S. *5-HT_{2A} receptors in suicidality and impulsivity*. Canadian Institutes of Health Research

Meyer, J.H., Wilson, A.A. & Houle, S. *Serotonin transporter occupancy found with PET during depression*. Eli Lilly Canada Inc.

Meyers, R. & Guttman, M. *PD gene study*. National Institutes of Health

Miller, B., DeWit, D., Macdonald, S., Maguin, G. & Safyer, A. *Family-based prevention for children of alcoholics*. National Institute on Alcohol Abuse and Alcoholism

Millson, M., Myers, T., Calzavara, L., Strike, C. & Cavellieri, W. *Understanding injection drug using in Toronto: Injection drug users' descriptions of their experiences and perceptions of HIV risk and prevention*. Ontario HIV Treatment Network

Millson, M., Strike, C., Fischer, B., Myers, T. & Calzavara, L. *Assessing the impact of low threshold methadone programs on HIV risk taking behaviours*. National Health Research and Development Program

Mundo E. *Investigating the role of the 5HT_{1D}beta receptor gene in obsessive-compulsive disorder*. University of Toronto

Myers, T., Bullock, S., Calzavara, L., Fischer, B. & Millson, P. *Dual risk for HIV? Drug use and sexual behaviour among MSM in Toronto*. Ontario HIV Treatment network

Naranjo, C.A., Busto, U.E. & Turksen, I.B. *Predicting response to pharmacotherapy in alcohol dependence using fuzzy logic: Naltrexone and citalopram*. Canadian Institutes of Health Research

Nelson, G. & Trainor, J.A. *Longitudinal study of consumer/survivor initiatives in Ontario*. Ontario Mental Health Foundation

- Nobrega, J.N.** *Brain substrates of side effect vulnerability after long-term neuroleptic treatment.* National Alliance for Research on Schizophrenia and Depression
- Nobrega, J.N. & Joffe, R.T.** *Brain thyroid hormones in models of depression.* Ontario Mental Health Foundation
- Noh, S. & Hyman, I.** *Pathway and barriers to mental health care for Ethiopians in Toronto.* Joint Centre of Excellence for Research on Immigration and Settlement
- Noh, S., Devins, G., Beiser, M., Rummens, A. & Kaspar, V.** *Immigration, resettlement, and mental health: Assessing resettlement impact.* Canadian Institutes of Health Research
- Noh, S. & Xinyin, C.** *A cross-cultural study of the stress process.* Social Sciences and Humanities Research Council of Canada
- O'Dowd, B.F. & George, S.R.** *The biology of dopamine and serotonin receptors.* Canadian Institutes of Health Research
- O'Grady, C. (P. Goering, Supervisor).** *Studentship.* Social Sciences and Humanities Research Council of Canada
- O'Loughlin, J., Paradis, G., Clarke, P. & Tyndale, R.** *A prospective study on the natural history of nicotine dependence.* National Cancer Institute of Canada
- Palmour, R.M., Vaccarino, F.J., Bateson, A.N., Baker, G.B., Ervin, F., Gutkowska, J. & Chaudhuri, A.** *CCK and anxiety: neurobiological characterization.* Canadian Institutes of Health Research
- Parikh, S.** *Developing a treatment optimization program for bipolar disorder: Integration of patient and provider interventions (New Investigator Fellowship).* Ontario Mental Health Foundation
- Paterson, A.** *Genetic and cellular studies of type I diabetes in Newfoundland.* Juvenile Diabetes Foundation International
- Paterson, A. & Pei, Y.** *Genetic mapping of type 1 diabetes susceptibility loci on human chromosomes 3 and 4.* Canadian Diabetes Association
- Penz, P. & Beiser, M.** *Analysis of survey data collected from sponsors of Kosovar refugees.* Citizenship and Immigration Canada — Ontario Administration of Settlement and Integration Services
- Perkins, D.O., Zipursky, R.B., Charles, C. & Lieberman, J.** *Prospective MRI and MRS neuroimaging in patients prodromal to schizophrenia.* Stanley Research Foundation
- Petronis, A.** *DNA methylation studies of DRD2 in schizophrenia.* Ontario Mental Health Foundation
- Petronis, A.** *Epigenetic analysis of class III VNTR alleles of the insulin gene.* Juvenile Diabetes Foundation International
- Petronis, A.** *Epigenetic regulation of the dopamine D2 receptor gene in alcoholism patients and controls.* Alcoholic Beverage Medical Research Foundation
- Petronis, A.** *Epigenetic search for retroviruses in major psychosis.* Stanley Research Foundation
- Petronis, A.** *Genetic and epigenetic analysis of CAG/CTG repeat sequences in major psychosis.* National Alliance for Research on Schizophrenia and Depression
- Petronis, A.** *Search for genetic and epigenetic risk factors in major psychosis.* Ontario Mental Health Foundation
- Petronis, A. & Baker, J.P.** *Epigenetic regulation of the tumor necrosis factor gene in Crohn's disease.* Crohn's and Colitis Foundation of Canada
- Petronis, A. & Janulaitis, A.** *Epigenetic study of the dopamine D2 receptor gene in schizophrenia.* North Atlantic Treaty Organization
- Rector, N.** *CBT for concurrent panic disorder and alcohol abuse.* CAMH Research Fund Award
- Rehm, J. & Fischer, B.** *Comparative over time analysis of IDU related harm levels and their determinants in Western jurisdictions.* Swiss Federal Office of Public Health
- Rehm, J., Miller, A., Ashley, M.J., Ferrence, R., Bondy, S., Rohan, T. & Jain, M.** *Smoking, alcohol consumption and mortality.* Canadian Institutes of Health Research
- Remington, G. & Kapur, S.** *The 5-HT₂ receptor occupancy of oral ziprasidone hydrochloride in patients with schizophrenia and schizoaffective disorder using positron emission tomography.* Pfizer Canada Inc.
- Remington, G., Kapur, S., Shammi, C. & Brook, S.** *Risperidone depot (microspheres) in the treatment of subjects with schizophrenia or schizoaffective disorder: An open label follow up trial.* Janssen-Ortho Inc.
- Richter, M.A., Kennedy, J. & Swinson, R.P.** *Obsessive compulsive disorder: An innovative genetic study.* Ontario Mental Health Foundation
- Richter, M.A., Kennedy, J., Swinson, R., Macciardi, F., Mundo, E., Summerfeldt, L. & Antony, M.** *Identifying the genetic basis of obsessive-compulsive disorder.* Canadian Institutes of Health Research
- Roder, J., Carlen, P., Hampson, D., Marks, A., McDonald, R., Pawson, T., Ralph, M., Salter, M., Smith, C., St. George-Hyslop, P., Van Tol, H.H.M. & Wojtowicz, M.** *Place cell equipment.* Canadian Institutes of Health Research

- Rootman, I., Ferrence, R., Ashley, M.J., Brown, K.S., Cohen, J., McDonald, P. & Stephens, T.** *Ontario Tobacco Research Unit*. Ontario Ministry of Health and Long-Term Care
- Ross, B.** *Abnormal phospholipid dependent signaling in schizophrenia: Potential for novel therapeutic approaches (New Investigator Fellowship)*. Ontario Mental Health Foundation
- Ross, B.** *Schizophrenia, eicosanoids and nicotine acid*. Ontario Mental Health Foundation
- Rotzinger, S.** *Immunohistochemical characterization of CCK peptide in sensitized rats*. CAMH Research Fund Award
- Rotzinger, S.** *The effects of lithium on the phosphoinositol cycle in bipolar patients*. Canadian Psychiatric Research Foundation
- Rotzinger, S.** *The role of glutamate and CRF projections in the amygdala in anxiety*. Alberta Heritage Foundation for Medical Research
- Rovet, J., Jain, U. & Daneman, D.** *Thyroid hormone, attention, and memory in congenital hypothyroidism and ADHD*. Canadian Institutes of Health Research
- Rummens, J.** *Canadian identities: An overview of Canadian research on identity*. Heritage Canada
- Rummens, J. & Seat, R.** *Assessing the impact of the Kosovo Crisis on the mental health and well being of newcomer Serbian children in the G.T.A.* Joint Centre of Excellence for Research on Immigration and Settlement-University of Toronto
- Rummens, J., Beiser, M., Hou, F. & Kaspar, V.** *Identity formation and negotiation among new Canadian youth*. Heritage Canada
- Rummens, J., Seat, R., Beiser, M., Noh, S. & Kaspar, V.** *Mental health of Serbian children*. Social Sciences and Humanities Research Council of Canada
- Rush, B., Goering, P., Gagne, M.A., Rogers, J., Norman, R. & Tolomiczenko, G.** *Enhancing the accessibility performance measurement and ongoing quality improvement of the Niagara Region Community Mental Health & Addiction System Phase IB*. Niagara Partners in Service
- Rush, B., Goering, P., McMains, S., Ogborne, A., Nadeau, L. & Roberts, G.** *Proposal for the development of guidelines for best practice for the treatment and rehabilitation of individuals with concurrent addiction and mental health problems*. Health Canada
- Rush, B., Norman, R., Kirsch, B. & Wild, C.** *Explaining outcomes: Developing instruments to assess the critical characteristics of community support programs for people with severe mental illness*. Ontario Mental Health Foundation
- Schachar, R., Kennedy, J.L. & Barr, C.L.** *Attention-deficit hyperactivity disorder: Cognitive phenotypes*. Ontario Mental Health Foundation
- Schachar, R., Tannock, R., Barr, C., Kennedy, J., Ickowicz, A. & Logan, G.** *Inhibitory control deficit as a diagnostic marker of attention deficit hyperactivity disorder*. Ontario Mental Health Foundation
- Seeman, M.V.** *Art show grant*. Eli Lilly, AstraZeneca and Pfizer
- Seeman, M.V. & Houle, S.** *Dopamine D2 receptor upregulation induced by traditional and novel neuroleptics*. Ontario Mental Health Foundation
- Seeman, M.V., Silvestri, S., Negrete, J.C. & Houle, S.** *Investigating antipsychotic induced dopamine D2 receptor upregulation and 5HT2 downregulation in humans using PET*. Schizophrenia Society (Bill Jeffries Schizophrenia Endowment)
- Seeman, P., George, S.R. & O'Dowd, B.F.** *Receptors mediating drug dependence*. National Institutes on Drug Abuse
- Segal, Z.V.** *Predicting depressive relapse through cognitive changes following mood induction (Senior Research Fellowship)*. Ontario Mental Health Foundation
- Segal, Z.V., M. Gemar, S. & Kennedy, S.** *Predicting depressive relapse through cognitive changes following mood challenge*. Canadian Institutes of Health Research
- Selby, P.** *The utility of serum methadone levels to monitor therapeutic response to methadone treated patients*. CAMH Research Fund Award
- Sellers, E.M., Busto, U.E. & Tyndale, R.F.** *Role of CYP2C19 in ethnic variation in drug sensitivity*. Canadian Institutes of Health Research
- Sellers, E.M. & Tyndale, R.F.** *Pharmacogenetic risk factors in drug abuse: CYP variants*. National Institute on Drug Abuse
- Sellers, E.M., Tyndale, R.F., Tomkins, D.M., Romach, M.K., Kaplan, H.L. & Lukas, S.E.** *Pharmacogenetic risk factors in drug abuse: Role of CYP2D6*. National Institute on Drug Abuse
- Setnik, B. (J. Nobrega, Supervisor).** *University of Toronto Open Fellowship*. University of Toronto
- Seto, M.** *Phallometric assessment of masochistic sexual preferences*. CAMH Research Fund Award
- Seto, M.C., Barbaree, H.E., Schneider, R., Lalumière, M.L., Rice, M.E., Harris, G.T. & Hilton, N.Z.** *Demands on forensic mental health services in Ontario*. Ontario Mental Health Foundation
- Shain, M. & Suurvali, H.** *Investing in comprehensive workplace health promotion: a resource*. Health Canada

- Shoulson, I. & Guttman, M.** *PHAROS study*. Huntington Study Group
- Simich, L.** *Preliminary research on the mental health implications of human trafficking*. CAMH Research Fund Award
- Simich, L. & Beiser, M.** *A study of secondary migration in Ontario*. Ontario Administration of Settlement and Integration Services, Citizenship and Immigration Canada
- Sobell, L.** *Fostering self change in problem drinkers*. National Institute on Alcohol Abuse and Alcoholism
- Stewart, M. & Beiser, M.** *Multicultural meanings and social support among immigrants and refugees*. Social Sciences and Humanities Research Council of Canada
- Sylvestre, J., Trainor, J., Aubry, T., Nelson, G., Ilves, P. & George, L.** *An evaluation of housing programs in Ontario*. Ontario Mental Health Foundation
- Tolomiczenko, G.** *Impact of personality factors on community treatment outcomes among persons with major mental illness*. National Alliance for Research on Schizophrenia and Depression
- Tolomiczenko, G. & Dewa, C.** *Mental health court evaluation project*. Ontario Mental Health Foundation
- Tomkins, D.** *Central role of 5-HT_{1B} receptors in controlling alcohol intake*. University of Toronto
- Tomkins, D. & O’Neill, M.** *Ethanol reinforcement: the role of 5-HT_{1B} receptors*. National Institute on Alcohol Abuse and Alcoholism
- Toneatto, T.** *Concurrent psychiatric disorder among problem gamblers: Prevalence and correlates*. Ontario Substance Abuse Bureau
- Toneatto, T. & Boughton, R.** *A Comparison of male and female gamblers in Ontario*. Ontario Substance Abuse Bureau
- Trainor, J., Sylvestre, J. & Ilves, P.** *Evaluating housing stability for a mentally ill population at risk for homelessness*. Canada Mortgage and Housing Corporation
- Turner, N.** *Adolescent understanding of the emotional and cognitive aspects of gambling: The development of a prevention strategy*. National Center for Responsible Gaming
- Turner, N. & Littman-Sharp, N.** *Winners: why do some develop gambling problems while other do not?* Ontario Ministry of Health and Long-Term Care
- Turner, N., Skinner, W. & Kelly, J.** *Project Weathervane: An instrument to measure gambling attitudes and perceptions*. Ontario Ministry of Health and Long-Term Care
- Tyndale, R.** *A propensity for alcohol drinking and elevated GABAA receptors: Cause and effect?* Ontario Mental Health Foundation
- Tyndale, R.** *Drug metabolism in the brain*. Canadian Institutes of Health Research
- Tyndale, R.** *Drug metabolism in the brain: Expression and regulation of cytochromes P450*. Canadian Institutes of Health Research
- Vaccarino, F.J.** *GRF: behavioural and physiological characterization*. Natural Sciences and Engineering Research Council
- Vaccarino, F.J.** *The role of cannabinoids in feeding*. Aventis
- Vaccarino, F.J.** *The role of CCK in psychostimulant drug craving*. Canadian Institutes of Health Research
- Vaccarino, F.J.** *University of Toronto Special Funds: MRC Special Grant*. University of Toronto
- Vaccarino, F.J., Palmour, R.M. & Ervin, F.** *CCK and anxiety: neurobehavioural characterization*. Canadian Institutes of Health Research
- Van Tol, H.H.M.** *SH3 domain interactions in dopamine receptors*. Canadian Institutes of Health Research
- Van Tol, H.H.M.** *The Kir3 - dopamine receptor complex*. Canadian Institutes of Health Research
- Van Tol, H.H.M., Wong, H.A.C. & Macciardi, F.** *Genetic studies with candidate genes in schizophrenia*. Ontario Mental Health Foundation
- Van Tol, H.H.M., Yu, X-Y. & Kennedy, J.L.** *Dopamine and psychomotor disease*. Canadian Institutes of Health Research
- Verhoeff, N.P.** *Imaging striatal synaptic dopamine levels and dopamine D2 receptor binding potential in schizophrenia patients and in control subjects using (¹¹C) raclopride PET (Postdoctoral Research Fellowship)*. Ontario Mental Health Foundation
- Verhoeff, P. (S. Kapur, Supervisor).** *Dopamine and D2 receptors in schizophrenia*. National Alliance for Research on Schizophrenia and Depression
- Vingilis, E., Mann, R., McLeod, A., Seeley, J., Beirness, D., Girling, S., Gliksman, L., Lane, P., Lamble, R., Single, E., Stoduto, G. & Voas, R.** *Health/safety impact of Ontario’s drinking hours*. National Institute on Alcohol Abuse and Alcoholism
- Warner, J.** *Narratives of gender and aggression*. Social Sciences and Humanities Research Council of Canada
- Warner, J., Ivis, F., Her, M., Rehm, J. & Gmel, G.** *Taxation, regulation of sales and their impact on consumption*. National Institute on Alcohol Abuse and Alcoholism

- Warsh, J.J.** *Molecular basis of calcium homeostasis abnormalities in bipolar disorder.* CAMH Research Fund Award
- Warsh, J.J.** *G protein-calcium ion link in bipolar affective disorder.* Canadian Institutes of Health Research
- Warsh, J.J.** *Molecular phenotyping in bipolar affective disorder.* National Alliance for Research on Schizophrenia and Depression
- Weiss, M., Hechtman, L., Connors, K., Brown, T., Johnson, N., Quinn, D. & Jain, U.** *Paroxetine in combination with dextroamphetamine on adult ADHD in comparison to IPT.* SmithKline Beecham Pharma Ltd.
- Whitehead, P.C., White, J., Maxim, P. & Ferrence, R.** *Exploring social cohesion in a globalizing era.* Social Sciences and Humanities Research Council of Canada
- Wilson, A., Ginovart, N. & Houle, S.** *Serotonin transporter radioligand: Part II validation in animals.* Eli Lilly Canada Inc.
- Wilson, A. & Houle, S.** *Serotonin transporter radioligand: Part II validation in humans.* Eli Lilly Canada Inc.
- Wilson, A., Meyer, J. & Houle, S.** *Serotonin transporter radioligand: Part II drug occupancy in humans.* Eli Lilly Canada Inc.
- Wong, A.H.C.** *Candidate genes and linkage disequilibrium studies in schizophrenia (Clinician Scientist Award).* Canadian Institutes of Health Research
- Wong, A.H.C.** *Genetic studies with candidate genes in schizophrenia.* Ontario Mental Health Foundation
- Wong, J.** *A randomized double blind trial of Raloxifene as an adjunct in the treatment of psychosis in women.* Canadian Psychiatric Research Foundation
- Wu, Z., Kaspar, V., Noh, S. & Chen, J.** *Immigrants, selectivity and mental health.* Canadian Population Health Initiative
- Yatham, L., Parikh, S.V., Kusumakar, V., Young, L.T., Beaulieu, S. & Silverstone, P.** *Canadian Consortium on Bipolar Disorder.* Canadian Institutes of Health Research
- Yoon, I-S. (J.J. Warsh, Supervisor).** *Orchard Task Force on Graduate Student Financial Support.* University of Toronto
- Yoon, I-S. (J.J. Warsh, Supervisor).** *University of Toronto Open Fellowship.* University of Toronto
- Yu, X-M.** *Canadian Institutes of Health Research Scholarship.* Canadian Institutes of Health Research
- Yu, X-M.** *Direct binding of dopamine D5 to GABA_A receptors and its function.* Canadian Institutes of Health Research
- Yu, X-M.** *From primary to secondary.* Ontario Neurotrauma Foundation
- Yu, X-M.** *Identification of novel mechanisms underlying the up-regulation of glutamate.* Ontario Neurotrauma Foundation
- Yu, X-M.** *Regulation of NMDA receptors by intracellular sodium.* Canadian Institutes of Health Research
- Zack, M. & Poulos, C.X.** *Pharmacological priming of gambling-related cognitions by amphetamine.* National Center for Responsible Gaming
- Zack, M., Poulos, C.X. & MacLeod, C.M.** *Effects of negative and positive affective cues on alcohol-related cognition and beer consumption in high and low anxiety sensitive drinkers.* Alcoholic Beverage Medical Research Foundation
- Zipursky, R.B., Epstein, I., Kumar, S., Lewis, R. & Christensen, B.** *Delaying or preventing psychosis onset: A randomized double-blind comparison of olanzapine and placebo in persons prodromal to psychosis.* Eli Lilly Canada Inc.
- Zipursky, R.B., Kapur, S., Christensen, B., Roy, P., Remington, G., Mikulis, D. & Damyanovich, A.** *Acute and long-term efficacy of olanzapine in first-episode psychotic disorders: A randomized double-blind comparison with haloperidol.* Eli Lilly Canada Inc.
- Zipursky, R.B., Kapur, S., Daskalakis, J., Papatheodorou, G. & Epstein, I.** *Seroquel in first episode psychosis: Treatment effects and PET evaluation.* AstraZeneca
- Zipursky, R.B., Kapur, S.K., Christensen, B., Roy, P., Remington, G., Mikulis, D. & Damyanovich, A.** *A single-site PET study to investigate the D2 and 5-HT₂ occupancy and its relationship to clinical outcome.* Eli Lilly Canada Inc.
- Zipursky, R.B., Lieberman, J., Green, A. & Sharma, T.** *Assessments of normal controls for comparison in assessments of acute and long-term efficacy of olanzapine in first-episode psychotic disorders: A randomized double-blind comparison with haloperidol.* Eli Lilly Canada Inc.